|
Infection
|
0.030 |
Biomarker
|
group |
LHGDN |
"The cell adhesion molecule ""CAR"" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution."
|
19119424 |
2009 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Aim:</b> Chimeric antigen receptor-engineered T (CAR-T) cells have gained huge success in treating hematological malignancies, yet the CD3ζ-based CAR-T therapies have not shown comparable clinical benefits in solid tumors.
|
31268375 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Areas covered</b>: CAR-T cell associated toxicities include cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES), alternatively known as immune effector cell-associated neurotoxicity syndrome (ICANS).
|
31219357 |
2019 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Areas covered</b>: CAR-T cell associated toxicities include cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES), alternatively known as immune effector cell-associated neurotoxicity syndrome (ICANS).
|
31219357 |
2019 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
<b>Purpose:</b> Metastasis to the brain from breast cancer remains a significant clinical challenge, and may be targeted with CAR-based immunotherapy.
|
29061641 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades.
|
31190844 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades.
|
31190844 |
2019 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Metastasis to the brain from breast cancer remains a significant clinical challenge, and may be targeted with CAR-based immunotherapy.
|
29061641 |
2018 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Metastasis to the brain from breast cancer remains a significant clinical challenge, and may be targeted with CAR-based immunotherapy.
|
29061641 |
2018 |
|
Acute leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
<i>MLL</i>-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?
|
31671855 |
2019 |
|
Infection
|
0.030 |
Biomarker
|
group |
LHGDN |
5-Fluorouracil-related enhancement of adenoviral infection is Coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes.
|
16937527 |
2006 |
|
Cardiomyopathy, Dilated
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart.
|
19957088 |
2010 |
|
Liver hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver hyperplasia (i.e., de novo growth and proliferation) is an alternate form of growth, caused by drugs that activate the nuclear receptor, CAR.
|
24104474 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-killing CAR therapies gain speed.
|
25583785 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-killing CAR therapies gain speed.
|
25583785 |
2015 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.
|
28960810 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.
|
28960810 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokine release syndrome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multivariable analysis.
|
29038338 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) is a common and potentially fatal complication of CAR-T cell therapy.
|
29443792 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy, and it is critical to have a reproducible and easy method to grade CRS after CAR T cell infusions.
|
29499750 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects.
|
30072559 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma.
|
30198955 |
2019 |
|
Behavioral and psychological symptoms of dementia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Neuropsychiatric symptoms are common among older people with neurocognitive disorders in CAR and ROC.
|
30255569 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer immunotherapy has made unprecedented breakthrough in the fields of chimeric antigen receptor-redirected T (CAR T) cell therapy and immune modulation.
|
30327605 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer immunotherapy has made unprecedented breakthrough in the fields of chimeric antigen receptor-redirected T (CAR T) cell therapy and immune modulation.
|
30327605 |
2018 |